Grifols posts transcript of Q2 2026 earnings call

Reuters2026/07/29 14:57

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Grifols’ Q2 2026 earnings call drew CEO Nacho Abia, CFO Rahul Srinivasan, Biopharma President Roland Wandeler, IR head Daniel Segarra.
H1 revenue reached EUR 3.57 billion; adjusted EBITDA EUR 854 million; free cash flow pre-M&A EUR 91 million; net leverage just under 4.2x.
Board started evaluating a potential IPO of the U.S. Biopharma business; management gave no timing, citing process constraints.
Immunoglobulins grew 12.8% at constant currency in H1; management expects mid-to-high single-digit IG growth in core U.S./Europe markets in H2.
Egypt plasma benefits start showing in 2026, with fuller impact in 2027; 29 U.S. donor-center closures to aid results late 2026, early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Grifols posts transcript of Q2 2026 earnings call

You may also like

Crypto prices